and of concomitant disease or other drug therapy. Prior to receiving Zomig, a cardiovascular evaluation is recommended for geriatric patients who have other cardiovascular risk factors (e.g ...
AstraZeneca has sold rights to its Zomig migraine drug to Grunenthal in a deal worth up to $302 million. The deal is part of AZ's ongoing tactic of selling off rights to older products to plump up ...